Please login to the form below

Not currently logged in
Email:
Password:

RTS,S

This page shows the latest RTS,S news and features for those working in and with pharma, biotech and healthcare.

NIH starts first trial of an antibody for malaria prevention

NIH starts first trial of an antibody for malaria prevention

A recombinant malaria vaccine called  Mosquirix (RTS, S/AS01) – developed by GlaxoSmithKline – was given a positive ‘scientific opinion’ by the EMA in 2015 after three decades of research, but is acknowledged

Latest news

  • GSK cues up regulatory filings for relapsing malaria drug GSK cues up regulatory filings for relapsing malaria drug

    One of the greatest challenges for patients with P vivax malaria is preventing relapses," said GSK's president of R&D Patrick Vallance. ... GSK is also developing a four-dose vaccine for malaria - RTS, S/AS01 - that has shown 31-56% protective efficacy

  • Dosing of GSK's malaria vaccine due to start in 2018 Dosing of GSK's malaria vaccine due to start in 2018

    Funding has now been secured for vaccination programmes using GlaxoSmithKline's malaria vaccine RTS, S, with the people due to receive the shots in 2018. ... RTS, S, acts against Plasmodium falciparum, the most deadly malaria parasite globally and the

  • Malaria vaccine is first to provide 'sustained protection' Malaria vaccine is first to provide 'sustained protection'

    The vaccine is based on inactivated Plasmodium falciparum sporozoites, a key stage in the parasite's life cycle. ... Mosquirix (formerly known as RTS, S) also targets P. falciparum - the most virulent form of malaria which affects 214m people a year and

  • World first as CHMP backs GSK malaria vaccine Mosquirix World first as CHMP backs GSK malaria vaccine Mosquirix

    Formerly known as RTS, S/ASO1, Mosquirix (Plasmodium falciparum and hepatitis B vaccine) was assessed under EMA rules that allow it to assess the quality, safety and efficacy  of a medicine ... The CHMP and GSK's biologics unit agreed measures to

  • Sharing knowledge to combat emerging threats Sharing knowledge to combat emerging threats

    GSK's work on a malaria vaccine is a good example of this. ... The company's RTS, S vaccine, filed for regulatory approval in Europe last year, is designed to protect against Plasmodium falciparum, the most dangerous of the mosquito-borne malaria

More from news
Approximately 2 fully matching, plus 14 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story
How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?
The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19
The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...

Infographics